"Paclitaxel" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
| Descriptor ID |
D017239
|
| MeSH Number(s) |
D02.455.426.392.368.242.888.777 D02.455.849.291.850.777
|
| Concept/Terms |
Taxol- Taxol
- Taxol A
- Bris Taxol
- Taxol, Bris
|
Below are MeSH descriptors whose meaning is more general than "Paclitaxel".
Below are MeSH descriptors whose meaning is more specific than "Paclitaxel".
This graph shows the total number of publications written about "Paclitaxel" by people in this website by year, and whether "Paclitaxel" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 2 | 4 |
| 1996 | 3 | 6 | 9 |
| 1997 | 5 | 2 | 7 |
| 1998 | 7 | 4 | 11 |
| 1999 | 1 | 2 | 3 |
| 2000 | 5 | 4 | 9 |
| 2001 | 1 | 7 | 8 |
| 2002 | 2 | 3 | 5 |
| 2003 | 3 | 7 | 10 |
| 2004 | 5 | 6 | 11 |
| 2005 | 2 | 11 | 13 |
| 2006 | 8 | 6 | 14 |
| 2007 | 1 | 9 | 10 |
| 2008 | 1 | 10 | 11 |
| 2009 | 1 | 4 | 5 |
| 2010 | 4 | 4 | 8 |
| 2011 | 1 | 12 | 13 |
| 2012 | 4 | 6 | 10 |
| 2013 | 0 | 7 | 7 |
| 2014 | 6 | 2 | 8 |
| 2015 | 3 | 7 | 10 |
| 2016 | 3 | 5 | 8 |
| 2017 | 1 | 2 | 3 |
| 2018 | 4 | 7 | 11 |
| 2019 | 5 | 9 | 14 |
| 2020 | 2 | 4 | 6 |
| 2021 | 7 | 13 | 20 |
| 2022 | 1 | 5 | 6 |
| 2023 | 2 | 0 | 2 |
| 2024 | 1 | 6 | 7 |
| 2025 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Paclitaxel" by people in Profiles.
-
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025 May 01; 11(5):492-501.
-
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecol Oncol. 2025 Mar; 194:145-152.
-
A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. Breast Cancer Res Treat. 2025 May; 211(1):111-119.
-
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
-
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy. Breast Cancer Res Treat. 2025 Jan; 209(1):147-159.
-
Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. Eur J Cancer. 2024 Sep; 209:114236.
-
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jul 01; 10(7):923-931.
-
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT. J Clin Oncol. 2024 Nov; 42(31):3652-3665.
-
Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024 Aug; 19(8):1228-1241.
-
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.